This topic has been canvassed previously. My understanding is that another phase 2 trial would be needed prior to a phase 3 in Fragile X and under the terms of NEU’s agreement with Acadia NEU fund 50% of trial costs after a certain undisclosed amount. Furthermore as Fragile X is a more common disorder than Rett syndrome the size and therefore cost of a phase 3 trial would likely be significantly more than the Rett phase 3.
As others have postulated if Acadia are any chance of taking NEU out after FDA approval they will not be progressing any program that could potentially raise NEU’s value other than Rett.
When asked about Acadia’s interest in Fragile X at the AGM this year Jon mentioned it was firmly on the back burner or words to that effect - IMO Fragile X is 5+ years away from adding any meaningful value and I have essentially assigned it zero value in my current models.
NEU Price at posting:
$7.49 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)